Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

Publisher： Karger

E-ISSN： 1421-9794|59|3|207-213

ISSN： 0009-3157

Source： Chemotherapy, Vol.59, Iss.3, 2013-12, pp. : 207-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

By  

Chemotherapy, Vol. 58, Iss. 5, 2013-01 ,pp. : 411-418

Karger

Access to resources Recommend Favorite

A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 1-7

Karger

Access to resources Recommend Favorite

Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study

By  

Chemotherapy, Vol. 58, Iss. 3, 2012-07 ,pp. : 225-232

Karger

Access to resources Recommend Favorite

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer

By Mancini Patrizia   Angeloni Antonio   Risi Emanuela   Orsi Errico   Mezi Silvia  

Cancers, Vol. 6, Iss. 4, 2014-10 ,pp. : 2187-2223

MDPI

Access to resources Recommend Favorite

Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting

By  

Chemotherapy, Vol. 59, Iss. 1, 2013-04 ,pp. : 1-7

Karger

Access to resources Recommend Favorite